Samruddhi Nandkumar Borate
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samruddhi Nandkumar Borate has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Swarnali Goswami
University of Mississippi
3 shared publications - Mohammed Zuber
Department of Clinical and Administrative Pharmacy College of Pharmacy University of Georgia Athens Georgia USA
2 shared publications - Prajakta P. Masurkar
University of Houston
2 shared publications - Akhila Yerubandi
Department of Clinical and Administrative Pharmacy College of Pharmacy University of Georgia Athens Georgia USA
1 shared publication - Alexis Hudson
Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, Atlanta, GA, 30322, United States, 1 4047129445
1 shared publication Annabel Nicholas
Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA
1 shared publication
Latest Publications
- 20 November 2026
- Published by Scifiniti Publishing in Evidence Synthesis in Healthcare Connect
Bridging Evidence Gaps in Diabetes Devices in India: The Role of HTA in Policy and Value Assessment
The prevalence of diabetes in India is rising rapidly, which results in substantial economic burden and productivity loss. Diabetes devices including continuous glucose monitors (CGMs), insulin pumps, and smart insulin pens, are critical for effective diabetes management. However, they remain underutilized due to high out-of-pocket expenditures, limited insurance coverage, and regional disparities in healthcare access. This paper highlights the need for economic evaluation of diabetes management devices in the Indian healthcare setting to improve accessibility and health outcomes. This paper also provides actionable insights for strengthening health technology assessment guidance for diabetes devices such as the need to establish real-world evidence (RWE) registries, incentivize local manufacturing, and integrate cost-effectiveness assessment into national/state health policy programs to improve access. We also provide guidance for future research to strengthen public-private partnership and incorporation of equity considerations in policy development. Strengthening economic evaluation is essential to achieve sustainable diabetes care in India.
- 20 November 2026
- Published by Scifiniti Publishing in Evidence Synthesis in Healthcare Connect
Bridging Evidence Gaps in Diabetes Devices in India: The Role of HTA in Policy and Value Assessment
The prevalence of diabetes in India is rising rapidly, which results in substantial economic burden and productivity loss. Diabetes devices including continuous glucose monitors (CGMs), insulin pumps, and smart insulin pens, are critical for effective diabetes management. However, they remain underutilized due to high out-of-pocket expenditures, limited insurance coverage, and regional disparities in healthcare access. This paper highlights the need for economic evaluation of diabetes management devices in the Indian healthcare setting to improve accessibility and health outcomes. This paper also provides actionable insights for strengthening health technology assessment guidance for diabetes devices such as the need to establish real-world evidence (RWE) registries, incentivize local manufacturing, and integrate cost-effectiveness assessment into national/state health policy programs to improve access. We also provide guidance for future research to strengthen public-private partnership and incorporation of equity considerations in policy development. Strengthening economic evaluation is essential to achieve sustainable diabetes care in India.
- Open Access
- 6 June 2026
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 28 (1)
Advancing HIV Pre-Exposure Prophylaxis (PrEP) for Women: A Review of Ongoing Trials on Drug Development and Behavioral Interventions
Purpose of Review: Cisgender women experience unique risks of human immunodeficiency virus (HIV) acquisition due to biological, social, and cultural factors. This narrative review provides an overview of ongoing clinical trials focused on emerging biomedical advances and behavioral interventions for pre-exposure prophylaxis (PrEP) among women. Recent Findings: The ClinicalTrials.gov database was queried for ongoing trials, and as of March 21, 2025, 6 eligible biomedical intervention and 22 behavioral intervention trials related to HIV PrEP among cisgender women. The sample size of the trials included ranged from 30 to 9,000 participants. The biomedical intervention trials enrolling women spanned diverse geographies and evaluated oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), long- acting cabotegravir, and lenacapavir/tenofovir alafenamide (TAF) regimens for PrEP. Long-acting agents examined in the trials offer innovative options for women to enhance treatment experience and overcome challenges associated with daily oral regimens. Behavioral interventions commonly involved mobile applications, social media, and counseling, with adherence and uptake as the most frequent outcomes assessed. Equity was a major focus in both biomedical and behavioral intervention trials, and trial populations included adolescent girls and young women from underserved communities around the world. Summary: Together, these findings underscore the progress in both biomedical and behavioral PrEP research for women. Future trials should continue to prioritize adolescents, young women, and participants from developing countries. Additionally, beyond long-acting formulations, other durable options need to be researched for cisgender women at risk of HIV.
- 6 June 2026
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 28 (1)
Open AccessAdvancing HIV Pre-Exposure Prophylaxis (PrEP) for Women: A Review of Ongoing Trials on Drug Development and Behavioral Interventions
Purpose of Review: Cisgender women experience unique risks of human immunodeficiency virus (HIV) acquisition due to biological, social, and cultural factors. This narrative review provides an overview of ongoing clinical trials focused on emerging biomedical advances and behavioral interventions for pre-exposure prophylaxis (PrEP) among women. Recent Findings: The ClinicalTrials.gov database was queried for ongoing trials, and as of March 21, 2025, 6 eligible biomedical intervention and 22 behavioral intervention trials related to HIV PrEP among cisgender women. The sample size of the trials included ranged from 30 to 9,000 participants. The biomedical intervention trials enrolling women spanned diverse geographies and evaluated oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), long- acting cabotegravir, and lenacapavir/tenofovir alafenamide (TAF) regimens for PrEP. Long-acting agents examined in the trials offer innovative options for women to enhance treatment experience and overcome challenges associated with daily oral regimens. Behavioral interventions commonly involved mobile applications, social media, and counseling, with adherence and uptake as the most frequent outcomes assessed. Equity was a major focus in both biomedical and behavioral intervention trials, and trial populations included adolescent girls and young women from underserved communities around the world. Summary: Together, these findings underscore the progress in both biomedical and behavioral PrEP research for women. Future trials should continue to prioritize adolescents, young women, and participants from developing countries. Additionally, beyond long-acting formulations, other durable options need to be researched for cisgender women at risk of HIV.
- Open Access
- 24 April 2026
- Published by Springer Nature in Health Services and Outcomes Research Methodology
Evaluating the psychometric properties of HIV/AIDS stigma among postgraduate medical students in Southern India: a Rasch analysis approach
The burden of HIV/AIDS in India is high, yet there is a dearth of scales measuring HIV/AIDS stigma that have been validated in an Indian health care population. Thus, this study aimed to assess the psychometric properties of the Health Care Provider HIV/AIDS Stigma Scale (HPASS) among Indian medical students. Data were collected from post-graduate (PG) medical students at a South Indian tertiary hospital via a structured online survey (March 2023-May 2024) including HPASS items and sociodemographics. The psychometric properties of HPASS were assessed using the principles of Item Response Theory. Respondents had a mean age of 25.9 years (SD = 2.5); 52% were female. Stereotyping and Discrimination subscales had satisfactory fit statistics, but two items of the Discrimination subscale did not fit the unidimensional construct and were therefore excluded. The 6-point rating scale performed poorly across subscales. The Stereotyping measure ranged from − 1.2 to 0.8 logits, Prejudice ranged from − 3 to 3 logits, Discrimination ranged from − 4 to 1.5 logits, indicating that Stereotyping subscale exhibited a reasonable spread in terms of the person and item distributions overlapping while the items in the two other subscales of Discrimination and Prejudice showed bias towards measuring higher level of Discrimination or Prejudice. Person separation index and person separation reliability were satisfactory for all the subscales. Stereotyping and Discrimination subscale had satisfactory construct validity, but Prejudice subscales and rating scales require further updates. This study is an important step in the direction of assessing HIV stigma in Indian medical students.
- 24 April 2026
- Published by Springer Nature in Health Services and Outcomes Research Methodology
Open AccessEvaluating the psychometric properties of HIV/AIDS stigma among postgraduate medical students in Southern India: a Rasch analysis approach
The burden of HIV/AIDS in India is high, yet there is a dearth of scales measuring HIV/AIDS stigma that have been validated in an Indian health care population. Thus, this study aimed to assess the psychometric properties of the Health Care Provider HIV/AIDS Stigma Scale (HPASS) among Indian medical students. Data were collected from post-graduate (PG) medical students at a South Indian tertiary hospital via a structured online survey (March 2023-May 2024) including HPASS items and sociodemographics. The psychometric properties of HPASS were assessed using the principles of Item Response Theory. Respondents had a mean age of 25.9 years (SD = 2.5); 52% were female. Stereotyping and Discrimination subscales had satisfactory fit statistics, but two items of the Discrimination subscale did not fit the unidimensional construct and were therefore excluded. The 6-point rating scale performed poorly across subscales. The Stereotyping measure ranged from − 1.2 to 0.8 logits, Prejudice ranged from − 3 to 3 logits, Discrimination ranged from − 4 to 1.5 logits, indicating that Stereotyping subscale exhibited a reasonable spread in terms of the person and item distributions overlapping while the items in the two other subscales of Discrimination and Prejudice showed bias towards measuring higher level of Discrimination or Prejudice. Person separation index and person separation reliability were satisfactory for all the subscales. Stereotyping and Discrimination subscale had satisfactory construct validity, but Prejudice subscales and rating scales require further updates. This study is an important step in the direction of assessing HIV stigma in Indian medical students.
- Open Access
- 1 March 2026
- Published by SAGE Publications in INQUIRY: The Journal of Health Care Organization, Provision, and Financing
- Vol. 63
Health Care-Related Tasks of Informal Dementia Caregivers in the U.S.: A Systematic Review with Narrative Synthesis
Health care-related tasks (e.g., making appointments, talking to providers) performed by informal caregivers caring for older adults with dementia have become increasingly common, yet the evidence on caregiving task profiles remains fragmented and has not been comprehensively synthesized. This is a systematic review with narrative synthesis of the patterns of health care-related tasks and the characteristics of caregivers who performed them. We searched PubMed, Embase, PsychInfo, Web of Science, and CINAHL databases. The identified tasks were grouped into health and medical care, advocacy and care coordination, and surrogate tasks. We also reported caregiver characteristics. We included 12 studies. Only 5 studies reported on racial and ethnic minority caregivers. Medication management was the most common health and medical care task. Only 1 study reported surrogate tasks, and 2 studies reported caregivers performing advocacy and care coordination tasks. This study is particularly timely given the recent implementation of the Centers for Medicare and Medicaid Services (CMS) Guiding an Improved Dementia Experience (GUIDE) Model, which includes caregiver support and education as core components of dementia care delivery. Systematically characterizing the health care-related tasks performed by dementia caregivers can inform the design, targeting, and evaluation of the GUIDE Model.
- 1 March 2026
- Published by SAGE Publications in INQUIRY: The Journal of Health Care Organization, Provision, and Financing
- Vol. 63
Open AccessHealth Care-Related Tasks of Informal Dementia Caregivers in the U.S.: A Systematic Review with Narrative Synthesis
Health care-related tasks (e.g., making appointments, talking to providers) performed by informal caregivers caring for older adults with dementia have become increasingly common, yet the evidence on caregiving task profiles remains fragmented and has not been comprehensively synthesized. This is a systematic review with narrative synthesis of the patterns of health care-related tasks and the characteristics of caregivers who performed them. We searched PubMed, Embase, PsychInfo, Web of Science, and CINAHL databases. The identified tasks were grouped into health and medical care, advocacy and care coordination, and surrogate tasks. We also reported caregiver characteristics. We included 12 studies. Only 5 studies reported on racial and ethnic minority caregivers. Medication management was the most common health and medical care task. Only 1 study reported surrogate tasks, and 2 studies reported caregivers performing advocacy and care coordination tasks. This study is particularly timely given the recent implementation of the Centers for Medicare and Medicaid Services (CMS) Guiding an Improved Dementia Experience (GUIDE) Model, which includes caregiver support and education as core components of dementia care delivery. Systematically characterizing the health care-related tasks performed by dementia caregivers can inform the design, targeting, and evaluation of the GUIDE Model.
- 5 November 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (1) , 102969
Using implementation science to evaluate perceived feasibility of pharmacy-based HIV services in the Southeastern United States
- 5 November 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (1) , 102969
Using implementation science to evaluate perceived feasibility of pharmacy-based HIV services in the Southeastern United States
- Open Access
- 12 September 2024
- Published by Wiley in Hematological Oncology
- Vol. 42 (5) , e3308
Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials
Bruton's tyrosine kinase (BTK) inhibitors are important therapeutic advances with promising efficacy outcomes in the treatment of patients with chronic lymphocytic leukemia and other B‐cell lymphoma subtypes. However, the utility of BTK inhibitors can be limited by adverse events such as infections. In this systematic review and meta‐analysis, we aim to determine the risk of various infections associated with BTK inhibitor monotherapy in B‐cell lymphoma patients. A comprehensive search was conducted in MEDLINE/PubMed, Embase, and Web of Science databases from their inception until October 2023. ClinicalTrials.gov, bibliographies, and relevant conference abstracts were also searched for additional records. Randomized controlled trials that included any B‐cell lymphoma patients treated with BTK inhibitor monotherapy and reported infection were included. Meta‐analysis was performed to calculate risk ratio (RR) using a random‐effects model in R Statistical Software, version 4.3.2. Of 3292 studies retrieved, we included 12 studies in this systematic review and meta‐analysis. The median age of patients across the study arms ranged between 64 and 73 years. The overall pooled RR for any grade upper respiratory tract infections (URTI) associated with BTK inhibitor treatment was 1.55 (95% Confidence Interval (CI) 1.22–1.97). The RR of grade ≥3 URTI was reported in 14 out of 1046 patients, yielding an RR of 1.46 (95% CI 0.61–3.54), which was not statistically significant. The pooled RR of any grade pneumonia was 1.20 (95% CI 0.68–2.10) and grade ≥3 pneumonia was 1.12 (95% CI 0.67–1.85), both of which were not statistically significant. Patients with B‐cell lymphoma who are undergoing BTK inhibitor monotherapy face an elevated risk of developing URTI. Clinicians prescribing BTK inhibitors should be aware of the potential infectious events that may occur. Close monitoring and the implementation of effective prophylactic measures are essential for managing these patients.
- 12 September 2024
- Published by Wiley in Hematological Oncology
- Vol. 42 (5) , e3308
Open AccessBruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials
Bruton's tyrosine kinase (BTK) inhibitors are important therapeutic advances with promising efficacy outcomes in the treatment of patients with chronic lymphocytic leukemia and other B‐cell lymphoma subtypes. However, the utility of BTK inhibitors can be limited by adverse events such as infections. In this systematic review and meta‐analysis, we aim to determine the risk of various infections associated with BTK inhibitor monotherapy in B‐cell lymphoma patients. A comprehensive search was conducted in MEDLINE/PubMed, Embase, and Web of Science databases from their inception until October 2023. ClinicalTrials.gov, bibliographies, and relevant conference abstracts were also searched for additional records. Randomized controlled trials that included any B‐cell lymphoma patients treated with BTK inhibitor monotherapy and reported infection were included. Meta‐analysis was performed to calculate risk ratio (RR) using a random‐effects model in R Statistical Software, version 4.3.2. Of 3292 studies retrieved, we included 12 studies in this systematic review and meta‐analysis. The median age of patients across the study arms ranged between 64 and 73 years. The overall pooled RR for any grade upper respiratory tract infections (URTI) associated with BTK inhibitor treatment was 1.55 (95% Confidence Interval (CI) 1.22–1.97). The RR of grade ≥3 URTI was reported in 14 out of 1046 patients, yielding an RR of 1.46 (95% CI 0.61–3.54), which was not statistically significant. The pooled RR of any grade pneumonia was 1.20 (95% CI 0.68–2.10) and grade ≥3 pneumonia was 1.12 (95% CI 0.67–1.85), both of which were not statistically significant. Patients with B‐cell lymphoma who are undergoing BTK inhibitor monotherapy face an elevated risk of developing URTI. Clinicians prescribing BTK inhibitors should be aware of the potential infectious events that may occur. Close monitoring and the implementation of effective prophylactic measures are essential for managing these patients.